11 recruiting, 7 terminated, 5 active not recruiting, 5 not yet recruiting. 15 Phase 1, 9 Phase 2, 7 Phase 3, 2 Early Phase 1, 1 Not applicable.
Follow Follicular Lymphoma (FL): new trials by email Literature Review of Follicular Lymphoma (FL) trials Research Report on Follicular Lymphoma (FL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T) - Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL) | Not applicable | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2026-09-01 | 2026-02-17 |
| Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma Sotoclax in combination with zanubrutinib and rituximab regimen - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 52 | 2026-09-01 | 2026-04-24 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma SCTB35 injection, Rituximab, Lenalidomide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | Sinocelltech Ltd. | 93 | 2026-06-09 | 2026-08-13 |
| A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma CT1182 injection - B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2026-04-30 | 2026-04-23 |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-10-28 |
| Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma TC011 single-arm - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | TICAROS Co., Ltd. | 40 | 2026-03-01 | 2026-01-22 |
| Long-term Study to Evaluate Safety and Persistence of GF-CART01 DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL) | Enrolling by invitation | GenomeFrontier Therapeutics TW Co., Ltd. | 18 | 2026-02-26 | 2026-06-11 | |
| Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies EXS73565 - Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 85 | 2025-03-31 | 2026-08-13 |
| Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma Zuberitamab, Bendamustine - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 50 | 2025-02-01 | 2025-01-03 |
| The Microbiome in Blood Cancer and HLH Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL) | Not yet recruiting | University of Nottingham | 750 | 2025-01-01 | 2024-12-16 | |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL Surovatamig - B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL) | Phase 2 | Recruiting | AstraZeneca | 270 | 2024-11-27 | 2026-10-14 |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Epcoritamab, Prednisone, Rituximab - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Genmab | 1095 | 2024-02-05 | 2026-08-04 |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 822 | 2023-12-12 | 2026-10-06 |
| A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 733 | 2023-11-14 | 2026-02-06 |
| A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 109 | 2023-10-02 | 2026-04-17 |
| Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms Routine care as per site standard. - Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting | iOMEDICO AG | 2950 | 2023-09-27 | 2026-07-13 | |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma Epcoritamab, Rituximab, Lenalidomide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Genmab | 549 | 2022-09-20 | 2026-07-08 |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NX-5948 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Recruiting | Nurix Therapeutics, Inc. | 572 | 2022-04-13 | 2026-07-02 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Terminated | MEI Pharma, Inc. | 82 | 2021-08-13 | 2024-11-04 |
Showing 20 of 35. Sign in to see all of them.
Lymphoma, Follicular (35) · Lymphoma, Mantle-Cell (16) · Lymphoma, Large B-Cell, Diffuse (15) · Lymphoma, B-Cell, Marginal Zone (14) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Lymphoma, Non-Hodgkin (8) · Waldenstrom Macroglobulinemia (8) · Lymphoma (7) · Lymphoma, B-Cell (6) · Recurrence (6) · Burkitt Lymphoma (5) · Dendritic Cell Sarcoma, Interdigitating (4) · Hematologic Neoplasms (4) · Neoplasms (4) · Hodgkin Disease (2)
Hemic and Lymphatic Diseases (35) · Immune System Diseases (35) · Immunoproliferative Disorders (35) · Lymphatic Diseases (35) · Lymphoproliferative Disorders (35) · Neoplasms by Histologic Type (35) · Neoplasms (31) · Lymphoma (28) · Lymphoma, Non-Hodgkin (27) · Lymphoma, B-Cell (18) · Disease Attributes (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Hematologic Diseases (14) · Chronic Disease (12)
Rituximab (8) · Cyclophosphamide (6) · Prednisone (5) · Bendamustine Hydrochloride (4) · Doxorubicin (4) · Lenalidomide (4) · Vincristine (4) · ME-401 (3) · Itraconazole (2) · Methylprednisolone (2) · Prednisolone (2) · tazemetostat (2) · zanubrutinib (2) · CF regimen (1) · PF06821497 (1)
MEI Pharma, Inc. (4) · Calibr, a division of Scripps Research (2) · Epizyme, Inc. (2) · Genmab (2) · Nurix Therapeutics, Inc. (2) · Regeneron Pharmaceuticals (2) · Sun Yat-sen University (2) · Acerta Pharma BV (1) · Amgen (1) · AstraZeneca (1) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (1) · GUSTAVO SALGUERO (1) · GenomeFrontier Therapeutics TW Co., Ltd. (1) · Hospices Civils de Lyon (1) · Huazhong University of Science and Technology (1)
United States (18) · Spain (12) · United Kingdom (12) · Poland (11) · Australia (10) · France (10) · China (9) · Taiwan (9) · Belgium (8) · Germany (8) · Italy (8) · South Korea (8) · Canada (7) · Austria (5) · Brazil (5)
Alain Monnereau, MD (1) · Gustavo Salguero, MD PhD MBA (1) · Ingo Tamm, PD Dr. (1) · Jens Kisro, Dr. (1) · Jianfeng Zhou, PhD, MD (1) · Mark J Bishton, MBChB, MRCP, FRCPath, PhD (1)
PMID 34515338, PMID 36375120, PMID 32175617, PMID 33653294, PMID 34531588, PMID 35835137, PMID 37874913, PMID 38143760, PMID 39705540, PMID 40809193, PMID 41371238, PMID 41633358
2023 (7), 2015 (1), 2018 (1)